DECR2: Key Enzyme in Peroxisomal TCA Cycle (G26063)

Target Name: DECR2

NCBI ID: G26063

DECR2

DECR2: Key Enzyme in Peroxisomal TCA Cycle

DECR2 (2,4-dienoyl-CoA reductase 2, peroxisomal) is a protein that is expressed in most tissues and is involved in the citric acid cycle, also known as the Krebs cycle or tricarboxylic acid (TCA) cycle. It is a key enzyme in the peroxisome, which is a organel that is found in most eukaryotic cells. The peroxisome is responsible for producing reactive oxygen species (ROS), which can cause damage to cells and contribute to a variety of diseases, including cancer.

DECR2 is a 23-kDa protein that is localized to the peroxisome. It is a member of the B-type cytoskeleton protein family and is involved in the assembly and function of peroxisomes. DECR2 is primarily localized to the peroxisomal cytoplasm and is also found in the peroxisomal membrane. It is a critical enzyme in the peroxisomal TCA cycle, as it is involved in the final step of the cycle, which is the production of ATP.

The peroxisomal TCA cycle is a critical pathway for the production of energy in eukaryotic cells. It is a source of reactive oxygen species, which can cause damage to cells and contribute to a variety of diseases, including cancer. The TCA cycle is also involved in the production of other important molecules, including amino acids, steroids, and other signaling molecules.

DECR2 is a key enzyme in the peroxisomal TCA cycle, as it is involved in the final step of the cycle, which is the production of ATP. It is a critical regulator of the cycle and is involved in the maintenance of the peroxisomal membrane stability. DECR2 is also involved in the regulation of other cellular processes, including cell signaling, cell division, and cell growth.

DECR2 is a protein that can be targeted as a drug or biomarker in a variety of diseases. For example, DECR2 has been shown to be involved in the development and progression of cancer. Studies have shown that DECR2 is highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. It is also involved in the regulation of cell signaling, which is a critical factor in the development of cancer.

DECR2 is also involved in the regulation of cell growth and cell division. It is a critical regulator of the cell cycle and is involved in the metaphase of cell division. DECR2 is also involved in the regulation of cell adhesion, which is a critical factor in the development of tissues and organs.

In conclusion, DECR2 is a protein that is involved in the peroxisomal TCA cycle and is critical for the production of ATP in eukaryotic cells. It is also involved in the regulation of other cellular processes, including cell signaling, cell division, and cell growth. As a result, DECR2 is a potential drug target and could be used as a biomarker for the diagnosis and treatment of various diseases.

Protein Name: 2,4-dienoyl-CoA Reductase 2

Functions: Auxiliary enzyme of beta-oxidation. Participates in the degradation of unsaturated fatty enoyl-CoA esters having double bonds in both even- and odd-numbered positions in peroxisome. Catalyzes the NADP-dependent reduction of 2,4-dienoyl-CoA to yield trans-3-enoyl-CoA. Has activity towards short and medium chain 2,4-dienoyl-CoAs, but also towards 2,4,7,10,13,16,19-docosaheptaenoyl-CoA, suggesting that it does not constitute a rate limiting step in the peroxisomal degradation of docosahexaenoic acid

The "DECR2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DECR2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets